PE20001110A1 - Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo - Google Patents

Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo

Info

Publication number
PE20001110A1
PE20001110A1 PE1999001027A PE00102799A PE20001110A1 PE 20001110 A1 PE20001110 A1 PE 20001110A1 PE 1999001027 A PE1999001027 A PE 1999001027A PE 00102799 A PE00102799 A PE 00102799A PE 20001110 A1 PE20001110 A1 PE 20001110A1
Authority
PE
Peru
Prior art keywords
weight
pharmaceutical composition
active agent
release
pharmaceutically active
Prior art date
Application number
PE1999001027A
Other languages
English (en)
Spanish (es)
Inventor
Rajen Shah
Arun P Patel
Roy T Sandry
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001110(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20001110A1 publication Critical patent/PE20001110A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE1999001027A 1998-10-14 1999-10-12 Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo PE20001110A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14

Publications (1)

Publication Number Publication Date
PE20001110A1 true PE20001110A1 (es) 2000-11-01

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001027A PE20001110A1 (es) 1998-10-14 1999-10-12 Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo

Country Status (30)

Country Link
EP (1) EP1121116B1 (enExample)
JP (2) JP2002527388A (enExample)
KR (1) KR100517090B1 (enExample)
CN (1) CN1196481C (enExample)
AR (2) AR020780A1 (enExample)
AT (1) ATE382345T1 (enExample)
AU (1) AU765475B2 (enExample)
BR (1) BR9911648A (enExample)
CA (1) CA2346868C (enExample)
CO (1) CO5140079A1 (enExample)
CY (1) CY1107874T1 (enExample)
DE (1) DE69937891T2 (enExample)
DK (1) DK1121116T3 (enExample)
ES (1) ES2297936T3 (enExample)
HK (1) HK1040920B (enExample)
HU (1) HUP0104268A3 (enExample)
ID (1) ID29350A (enExample)
IL (2) IL142375A0 (enExample)
MY (1) MY121105A (enExample)
NO (1) NO327285B1 (enExample)
NZ (1) NZ511010A (enExample)
PE (1) PE20001110A1 (enExample)
PL (1) PL198850B1 (enExample)
PT (1) PT1121116E (enExample)
RU (1) RU2259826C2 (enExample)
SK (2) SK286595B6 (enExample)
TR (1) TR200101088T2 (enExample)
TW (1) TW577738B (enExample)
WO (1) WO2000021525A2 (enExample)
ZA (1) ZA200103001B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CZ20024015A3 (cs) 2000-06-09 2003-04-16 Lek Pharmaceutical D.D. Stabilní farmaceutický produkt a jeho formulace
WO2002026214A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2004024184A1 (ja) * 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
CA2615941A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
RU2008136767A (ru) * 2006-02-24 2010-03-27 Тева Фармасьютикл Индастриес Лтд. (Il) Фармацевтическая композиция флувастатина натрия
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
WO2014110248A1 (en) * 2013-01-09 2014-07-17 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
US10377708B2 (en) 2017-12-05 2019-08-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
SG11202102204PA (en) 2018-09-25 2021-04-29 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
US20220265586A1 (en) * 2019-06-10 2022-08-25 Ponce De Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
EP0465096A1 (en) * 1990-06-26 1992-01-08 Merck & Co. Inc. Plasma cholesterol level lowering composition
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
AU725622B2 (en) * 1995-12-22 2000-10-19 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2346868A1 (en) 2000-04-20
IL142375A (en) 2012-01-31
PL348109A1 (en) 2002-05-06
KR100517090B1 (ko) 2005-09-27
KR20010080156A (ko) 2001-08-22
CO5140079A1 (es) 2002-03-22
JP2006298945A (ja) 2006-11-02
JP4938383B2 (ja) 2012-05-23
HK1040920A1 (en) 2002-06-28
IL142375A0 (en) 2002-03-10
SK286595B6 (sk) 2009-01-07
SK5092001A3 (en) 2001-09-11
AR020780A1 (es) 2002-05-29
CY1107874T1 (el) 2013-06-19
NO20011695L (no) 2001-05-30
DE69937891D1 (de) 2008-02-14
ZA200103001B (en) 2002-07-11
AU6090999A (en) 2000-05-01
CN1196481C (zh) 2005-04-13
ATE382345T1 (de) 2008-01-15
NO20011695D0 (no) 2001-04-04
EP1121116A2 (en) 2001-08-08
TW577738B (en) 2004-03-01
ES2297936T3 (es) 2008-05-01
RU2259826C2 (ru) 2005-09-10
WO2000021525A3 (en) 2000-08-10
CN1328454A (zh) 2001-12-26
PT1121116E (pt) 2008-03-12
NO327285B1 (no) 2009-06-02
NZ511010A (en) 2003-10-31
HUP0104268A2 (hu) 2002-04-29
EP1121116B1 (en) 2008-01-02
JP2002527388A (ja) 2002-08-27
AR069281A2 (es) 2010-01-13
DK1121116T3 (da) 2008-05-13
SK286596B6 (sk) 2009-01-07
AU765475B2 (en) 2003-09-18
HUP0104268A3 (en) 2002-06-28
DE69937891T2 (de) 2008-12-11
WO2000021525A2 (en) 2000-04-20
HK1040920B (zh) 2005-07-29
CA2346868C (en) 2008-09-09
ID29350A (id) 2001-08-23
BR9911648A (pt) 2001-03-20
MY121105A (en) 2005-12-30
PL198850B1 (pl) 2008-07-31
TR200101088T2 (tr) 2001-10-22

Similar Documents

Publication Publication Date Title
PE20001110A1 (es) Composicion farmaceutica de liberacion sostenida, y metodo para liberar un agente farmaceuticamente activo
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
CA2385890A1 (en) Controlled release compositions comprising nimesulide
MEP30808A (en) Composition comprising a cholesterol absorption inhibitor, an hmgcoa reductase inhibitor and a stabilizing agent
RU2007126483A (ru) Гетероциклические ингибиторы аспартилпротеазы
BR9913221A (pt) Composições catalisadoras sustentadas altamente ativas
MA31432B1 (fr) Metabolites de derives de (thio) carbamoyl-cyclohexane
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
PE20020254A1 (es) Derivados de piridina
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
GEP20053548B (en) Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents
IE970731A1 (en) Product and method for the treatment of hyperlipidemia
ATE234282T1 (de) Polymorphe verbindungen
PL358103A1 (pl) Hydrofilowe molekularne roztwory dyspersyjne karwedilolu
SE9603667D0 (sv) Pharmaceutical compositions
TR200200518T2 (tr) Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
CA2294812A1 (fr) Composition pharmaceutique solide contenant des derives de benzofuranne
PE20020833A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponisibilidad oral
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
CO5190673A1 (es) Nueva composicion y uso liberacion modificada
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
RU2008102238A (ru) Таблетка, содержащая труднорастворимый активный ингредиент
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term